1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Hepatic (Liver) Tumor – Pipeline Review, H1 2013

Hepatic (Liver) Tumor – Pipeline Review, H1 2013

  • February 2013
  • -
  • Global Markets Direct
  • -
  • 38 pages

Hepatic (Liver) Tumor – Pipeline Review, H1 2013

Summary

Global Markets Direct’s, 'Hepatic (Liver) Tumor - Pipeline Review, H1 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Hepatic (Liver) Tumor, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Hepatic (Liver) Tumor. Hepatic (Liver) Tumor - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Hepatic (Liver) Tumor.
- A review of the Hepatic (Liver) Tumor products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Hepatic (Liver) Tumor pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Hepatic (Liver) Tumor.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Hepatic (Liver) Tumor pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

Table Of Contents

Hepatic (Liver) Tumor - Pipeline Review, H1 2013
Table of Contents

Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Hepatic (Liver) Tumor Overview 6
Therapeutics Development 7
An Overview of Pipeline Products for Hepatic (Liver) Tumor 7
Hepatic (Liver) Tumor Therapeutics under Development by Companies 9
Hepatic (Liver) Tumor Therapeutics under Investigation by Universities/Institutes 10
Early Clinical Stage Products 11
Comparative Analysis 11
Pre-Clinical Stage Products 12
Comparative Analysis 12
Hepatic (Liver) Tumor Therapeutics - Products under Development by Companies 13
Hepatic (Liver) Tumor Therapeutics - Products under Investigation by Universities/Institutes 14
Companies Involved in Hepatic (Liver) Tumor Therapeutics Development 15
OXiGENE, Inc. 15
Transgene SA 16
Onconova Therapeutics, Inc 17
Hepatic (Liver) Tumor - Therapeutics Assessment 18
Assessment by Monotherapy Products 18
Assessment by Combination Products 19
Assessment by Route of Administration 20
Assessment by Molecule Type 22
Drug Profiles 24
OXi-4503 - Drug Profile 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
rigosertib + [irinotecan hydrochloride] - Drug Profile 26
Product Description 26
Mechanism of Action 26
RandD Progress 26
rigosertib + [oxaliplatin] - Drug Profile 28
Product Description 28
Mechanism of Action 28
RandD Progress 28
TG-4023 + [flucytosine] - Drug Profile 30
Product Description 30
Mechanism of Action 30
RandD Progress 30
BO-110 - Drug Profile 31
Product Description 31
Mechanism of Action 31
RandD Progress 31
Hepatic (Liver) Tumor Therapeutics - Drug Profile Updates 32
Hepatic (Liver) Tumor Therapeutics - Dormant Products 34
Hepatic (Liver) Tumor - Product Development Milestones 35
Featured News and Press Releases 35
Nov 01, 2010: Cleveland BioLabs Initiates Phase IB Trial For Prototype Curaxin CBLC102 In Russia 35
Apr 19, 2010: Positive Interim Results for JX-594 Randomized Phase II Liver Cancer Trial Presented at Major International Conference (EASL) 35
Appendix 37
Methodology 37
Coverage 37
Secondary Research 37
Primary Research 37
Expert Panel Validation 37
Contact Us 38
Disclaimer 38



List of Tables

Number of Products Under Development for Hepatic (Liver) Tumor, H1 2013 7
Products under Development for Hepatic (Liver) Tumor - Comparative Analysis, H1 2013 8
Number of Products under Development by Companies, H1 2013 9
Number of Products under Investigation by Universities/Institutes, H1 2013 10
Comparative Analysis by Early Clinical Stage Development, H1 2013 11
Comparative Analysis by Pre-Clinical Stage Development, H1 2013 12
Products under Development by Companies, H1 2013 13
Products under Investigation by Universities/Institutes, H1 2013 14
OXiGENE, Inc., H1 2013 15
Transgene SA, H1 2013 16
Onconova Therapeutics, Inc, H1 2013 17
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Stage and Molecule Type, H1 2013 23
Hepatic (Liver) Tumor Therapeutics - Drug Profile Updates 32
Hepatic (Liver) Tumor Therapeutics - Dormant Products 34



List of Figures

Number of Products under Development for Hepatic (Liver) Tumor, H1 2013 7
Products under Development for Hepatic (Liver) Tumor - Comparative Analysis, H1 2013 8
Products under Development by Companies, H1 2013 9
Products under Investigation by Universities/Institutes, H1 2013 10
Early Clinical Stage Products, H1 2013 11
Pre-Clinical Stage Products, H1 2013 12
Assessment by Monotherapy Products, H1 2013 18
Assessment by Combination Products, H1 2013 19
Assessment by Route of Administration, H1 2013 20
Assessment by Stage and Route of Administration, H1 2013 21
Assessment by Molecule Type, H1 2013 22
Assessment by Stage and Molecule Type, H1 2013 23

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests,  Opport

2016 Immunodiagnostic Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts for 100 Special Chemistry, Drug of Abuse, Endocrine Function, Immunoprotein, Therapeutic Drug Monitoring, and Tumor Marker Tests, Opport

  • $ 47500
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-company survey from VPGMarketResearch.com contains 1,650 pages and 890 tables. The report provides a granular strategic analysis of over 100 clinical chemistry, TDM, endocrine, cancer, immunoprotein ...

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

2016 Tumor Markers in 32 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Test--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Emerging Technologies, Opportunities for Suppliers

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

2016 Cancer Diagnostic Testing Analyzers and Reagents in 33 Countries: Supplier Shares and Strategies, Sales Segment Forecasts by Tumor Marker--Oncogenes, Biochemical Markers, Lymphokines, GFs, CSFs, Hormones, Immunohistochemical Stains--Technology Trends

  • $ 47400
  • Industry report
  • October 2016
  • by Venture Planning Group

This new 33-country survey from VPGMarketResearch.com contains over 1,300 pages and 500 tables. The survey is designed to assist diagnostics industry executives, as well as companies planning to diversify ...


ref:plp2013

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.